Journal of Cancer Research and Clinical Oncology

, Volume 138, Issue 3, pp 439–449

RUNX3 is involved in caspase-3-dependent apoptosis induced by a combination of 5-aza-CdR and TSA in leukaemia cell lines

  • Feng-Xian Zhai
  • Xiang-Fu Liu
  • Rui-Fang Fan
  • Zi-Jie Long
  • Zhi-Gang Fang
  • Ying Lu
  • Yong-Jiang Zheng
  • Dong-Jun Lin
Original Paper

DOI: 10.1007/s00432-011-1113-y

Cite this article as:
Zhai, FX., Liu, XF., Fan, RF. et al. J Cancer Res Clin Oncol (2012) 138: 439. doi:10.1007/s00432-011-1113-y

Abstract

Purpose

Epigenetic therapy has had a significant impact on the management of haematologic malignancies. The aim of this study was to assess whether 5-aza-CdR and TSA inhibit the growth of leukaemia cells and induce caspase-3-dependent apoptosis by upregulating RUNX3 expression.

Methods

K562 and Reh cells were treated with 5-aza-CdR, TSA or both compounds. RT-PCR and Western blot analyses were used to examine the expression of RUNX3 at the mRNA and protein levels, respectively. Immunofluorescence microscopy was used to detect the cellular location of RUNX3. Additionally, after K562 cells were transfected with RUNX3, apoptosis and proliferation were studied using Annexin V staining and MTT assays.

Results

The expression of RUNX3 in leukaemia cell lines was markedly less than that in the controls. Demethylating drug 5-aza-CdR could induce RUNX3 expression, but the combination of TSA and 5-aza-CdR had a greater effect than did treatment with a single compound. The combination of 5-aza-CdR and TSA induced the translocation of RUNX3 from the cytoplasm into the nucleus. TSA enhanced apoptosis induced by 5-aza-CdR, and Annexin V and Hoechst 33258 staining showed that the combination induced apoptosis but not necrosis. Furthermore, apoptosis was dependent on the caspase-3 pathway. RUNX3 overexpression in K562 cells led to growth inhibition and apoptosis and potentiated the effects of 5-aza-CdR induction.

Conclusion

RUNX3 plays an important role in leukaemia cellular functions, and the induction of RUNX3-mediated effects may contribute to the therapeutic value of combination TSA and 5-aza-CdR treatment.

Keywords

Runt-related transcription factor 3 (RUNX3) Chronic myeloid leukaemia (CML) 5-aza-2-deoxycytidine (5-aza-CdR) TSA (trichostatin A) 

Abbreviations

RUNX3

Runt-related transcription factor 3

CpG

Cytosine phosphate guanine

5-aza-CR

5-aza-cytidine

5-aza-CdR

5-aza-2-deoxycytidine

CML

Chronic myeloid leukaemia

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Feng-Xian Zhai
    • 1
  • Xiang-Fu Liu
    • 1
  • Rui-Fang Fan
    • 1
  • Zi-Jie Long
    • 1
  • Zhi-Gang Fang
    • 1
  • Ying Lu
    • 1
  • Yong-Jiang Zheng
    • 1
  • Dong-Jun Lin
    • 1
  1. 1.Department of Hematology, The Third Affiliated HospitalSun Yat-Sen UniversityGuangzhouChina

Personalised recommendations